Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 + T cell responses.

Malo CS, Huggins MA, Goddery EN, Tolcher HMA, Renner DN, Jin F, Hansen MJ, Pease LR, Pavelko KD, Johnson AJ.

Nat Commun. 2018 Feb 12;9(1):633. doi: 10.1038/s41467-018-03037-x.

2.

B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System.

Pavelko KD, Bell MP, Harrington SM, Dong H.

Front Immunol. 2017 Nov 9;8:1532. doi: 10.3389/fimmu.2017.01532. eCollection 2017.

3.

Brain atrophy in picornavirus-infected FVB mice is dependent on the H-2Db class I molecule.

Huseby Kelcher AM, Atanga PA, Gamez JD, Cumba Garcia LM, Teclaw SJ, Pavelko KD, Macura SI, Johnson AJ.

FASEB J. 2017 Jun;31(6):2267-2275. doi: 10.1096/fj.201601055R. Epub 2017 Feb 10.

4.

Modulatory effects of perforin gene dosage on pathogen-associated blood-brain barrier (BBB) disruption.

Willenbring RC, Jin F, Hinton DJ, Hansen M, Choi DS, Pavelko KD, Johnson AJ.

J Neuroinflammation. 2016 Aug 31;13(1):222. doi: 10.1186/s12974-016-0673-9.

5.

The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma.

Malo CS, Renner DN, Huseby Kelcher AM, Jin F, Hansen MJ, Pavelko KD, Johnson AJ.

PLoS One. 2016 Aug 25;11(8):e0162064. doi: 10.1371/journal.pone.0162064. eCollection 2016.

6.

Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.

Bell MP, Pavelko KD.

Mol Cancer Ther. 2016 Mar;15(3):523-30. doi: 10.1158/1535-7163.MCT-15-0459. Epub 2016 Jan 28.

7.

Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.

Renner DN, Malo CS, Jin F, Parney IF, Pavelko KD, Johnson AJ.

Neurotherapeutics. 2016 Jan;13(1):226-36. doi: 10.1007/s13311-015-0407-1.

8.

A Versatile Simple Capture Assay for Assessing the Structural Integrity of MHC Multimer Reagents.

Reed BK, Chopp LB, Malo CS, Renner DN, Van Keulen VS, Girtman MA, Nevala WN, Pavelko KD, Gil D, Schrum AG, Johnson AJ, Pease LR.

PLoS One. 2015 Sep 21;10(9):e0137984. doi: 10.1371/journal.pone.0137984. eCollection 2015.

9.

Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.

Renner DN, Jin F, Litterman AJ, Balgeman AJ, Hanson LM, Gamez JD, Chae M, Carlson BL, Sarkaria JN, Parney IF, Ohlfest JR, Pirko I, Pavelko KD, Johnson AJ.

PLoS One. 2015 May 1;10(5):e0125565. doi: 10.1371/journal.pone.0125565. eCollection 2015.

10.

A CD8 T-cell epitope variant enhances immune targeting to a recombinant picornavirus vaccine antigen.

Bell MP, Renner DN, Johnson AJ, Pavelko KD.

Viral Immunol. 2014 Sep;27(7):361-6. doi: 10.1089/vim.2014.0045. Epub 2014 Jul 15.

11.

An elite controller of picornavirus infection targets an epitope that is resistant to immune escape.

Bell MP, Renner DN, Johnson AJ, Pavelko KD.

PLoS One. 2014 Apr 7;9(4):e94332. doi: 10.1371/journal.pone.0094332. eCollection 2014.

12.

The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.

Pavelko KD, Bell MP, Karyampudi L, Hansen MJ, Allen KS, Knutson KL, Pease LR.

Mol Ther. 2013 May;21(5):1087-95. doi: 10.1038/mt.2013.52. Epub 2013 Apr 9.

13.

Preserved vascular integrity and enhanced survival following neuropilin-1 inhibition in a mouse model of CD8 T cell-initiated CNS vascular permeability.

Suidan GL, Dickerson JW, Johnson HL, Chan TW, Pavelko KD, Pirko I, Seroogy KB, Johnson AJ.

J Neuroinflammation. 2012 Sep 18;9:218. doi: 10.1186/1742-2094-9-218.

14.

Nonequivalence of classical MHC class I loci in ability to direct effective antiviral immunity.

Pavelko KD, Mendez-Fernandez Y, Bell MP, Hansen MJ, Johnson AJ, David CS, Rodriguez M, Pease LR.

PLoS Pathog. 2012 Feb;8(2):e1002541. doi: 10.1371/journal.ppat.1002541. Epub 2012 Feb 23.

15.

Contrasting roles for CD4 vs. CD8 T-cells in a murine model of virally induced "T1 black hole" formation.

Pirko I, Chen Y, Lohrey AK, McDole J, Gamez JD, Allen KS, Pavelko KD, Lindquist DM, Dunn RS, Macura SI, Johnson AJ.

PLoS One. 2012;7(2):e31459. doi: 10.1371/journal.pone.0031459. Epub 2012 Feb 13.

16.

Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy.

Pavelko KD, Girtman MA, Mitsunaga Y, Mendez-Fernandez YV, Bell MP, Hansen MJ, Allen KS, Rodriguez M, Pease LR.

PLoS One. 2011;6(5):e20217. doi: 10.1371/journal.pone.0020217. Epub 2011 May 20.

17.

Retraction: CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.

Pavelko KD, Hansen MJ, Pease LR.

Cancer Res. 2010 Nov 15;70(22):9529. doi: 10.1158/0008-5472.CAN-10-3463. Epub 2010 Nov 2. No abstract available.

18.

Retraction: An effective vaccine strategy protective against antigenically distinct tumor variants.

Pavelko KD, Hansen MJ, Pease LR, Heckman KL.

Cancer Res. 2010 Nov 15;70(22):9528. doi: 10.1158/0008-5472.CAN-10-3462. Epub 2010 Nov 2. No abstract available.

19.

Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R.

Cancer Res. 2010 Jun 1;70(11):4539-49. doi: 10.1158/0008-5472.CAN-09-4658. Epub 2010 May 18.

20.

CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.

Pavelko KD, Hansen MJ, Pease LR.

Cancer Res. 2009 Apr 1;69(7):3114-20. doi: 10.1158/0008-5472.CAN-08-2448. Epub 2009 Mar 10. Retraction in: Pavelko KD, Hansen MJ, Pease LR. Cancer Res. 2010 Nov 15;70(22):9529.

21.

An effective vaccine strategy protective against antigenically distinct tumor variants.

Pavelko KD, Heckman KL, Hansen MJ, Pease LR.

Cancer Res. 2008 Apr 1;68(7):2471-8. doi: 10.1158/0008-5472.CAN-07-5937. Retraction in: Pavelko KD, Hansen MJ, Pease LR, Heckman KL. Cancer Res. 2010 Nov 15;70(22):9528.

22.

Human HLA-DR transgenes protect mice from fatal virus-induced encephalomyelitis and chronic demyelination.

Rodriguez M, Zoecklein L, Kerkvliet JG, Pavelko KD, Papke L, Howe CL, Pease LR, David C.

J Virol. 2008 Apr;82(7):3369-80. doi: 10.1128/JVI.02243-07. Epub 2008 Jan 30.

23.

Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ.

Heckman KL, Schenk EL, Radhakrishnan S, Pavelko KD, Hansen MJ, Pease LR.

Eur J Immunol. 2007 Jul;37(7):1827-35.

24.
25.

STAT4- and STAT6-signaling molecules in a murine model of multiple sclerosis.

Rodriguez M, Zoecklein L, Gamez JD, Pavelko KD, Papke LM, Nakane S, Howe C, Radhakrishnan S, Hansen MJ, David CS, Warrington AE, Pease LR.

FASEB J. 2006 Feb;20(2):343-5. Epub 2005 Dec 13.

PMID:
16352646
26.

A 40-cM region on chromosome 14 plays a critical role in the development of virus persistence, demyelination, brain pathology and neurologic deficits in a murine viral model of multiple sclerosis.

Nakane S, Zoecklein LJ, Gamez JD, Papke LM, Pavelko KD, Bureau JF, Brahic M, Pease LR, Rodriguez M.

Brain Pathol. 2003 Oct;13(4):519-33.

PMID:
14655757
27.
28.

Direct comparison of demyelinating disease induced by the Daniel's strain and BeAn strain of Theiler's murine encephalomyelitis virus.

Zoecklein LJ, Pavelko KD, Gamez J, Papke L, McGavern DB, Ure DR, Njenga MK, Johnson AJ, Nakane S, Rodriguez M.

Brain Pathol. 2003 Jul;13(3):291-308.

29.

Interleukin-6 protects anterior horn neurons from lethal virus-induced injury.

Pavelko KD, Howe CL, Drescher KM, Gamez JD, Johnson AJ, Wei T, Ransohoff RM, Rodriguez M.

J Neurosci. 2003 Jan 15;23(2):481-92.

30.

Transgenic expression of Theiler's murine encephalomyelitis virus genes in H-2(b) mice inhibits resistance to virus-induced demyelination.

Lin X, Njenga MK, Johnson AJ, Pavelko KD, David CS, Pease LR, Rodriguez M.

J Virol. 2002 Aug;76(15):7799-811.

31.
32.

Preservation of motor function by inhibition of CD8+ virus peptide-specific T cells in Theiler's virus infection.

Johnson AJ, Upshaw J, Pavelko KD, Rodriguez M, Pease LR.

FASEB J. 2001 Dec;15(14):2760-2. Epub 2001 Oct 15.

PMID:
11606479
33.

The CD4-mediated immune response is critical in determining the outcome of infection using Theiler's viruses with VP1 capsid protein point mutations.

Rodriguez M, Roos RP, McGavern D, Zoecklein L, Pavelko K, Sang H, Lin X.

Virology. 2000 Sep 15;275(1):9-19.

34.

HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis.

Pavelko KD, Drescher KM, McGavern DB, David CS, Rodriguez M.

Mol Cell Neurosci. 2000 Jun;15(6):495-509.

35.

CD40L is critical for protection from demyelinating disease and development of spontaneous remyelination in a mouse model of multiple sclerosis.

Drescher KM, Zoecklein LJ, Pavelko KD, Rivera-Quinones C, Hollenbaugh D, Rodriguez M.

Brain Pathol. 2000 Jan;10(1):1-15.

PMID:
10668891
36.
37.

Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination.

Pavelko KD, van Engelen BG, Rodriguez M.

J Neurosci. 1998 Apr 1;18(7):2498-505.

38.

5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus.

Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M.

Exp Neurol. 1997 Sep;147(1):123-9.

PMID:
9294409
39.

Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination.

van Engelen BG, Pavelko KD, Rodriguez M.

Mult Scler. 1997 Apr;3(2):76-9. Review.

PMID:
9291157
40.

The balance between persistent virus infection and immune cells determines demyelination.

Rodriguez M, Pavelko KD, Njenga MK, Logan WC, Wettstein PJ.

J Immunol. 1996 Dec 15;157(12):5699-709.

PMID:
8955224
41.

Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.

Njenga MK, Pavelko KD, Baisch J, Lin X, David C, Leibowitz J, Rodriguez M.

J Virol. 1996 Mar;70(3):1729-37.

42.

Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Rodriguez M, Pavelko K, Coffman RL.

J Virol. 1995 Nov;69(11):7286-90.

43.

Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

van Engelen BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M.

J Neurol Neurosurg Psychiatry. 1994 Nov;57 Suppl:65-8. Review.

44.

Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis.

Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL.

J Immunol. 1994 Oct 15;153(8):3811-21.

PMID:
7930598

Supplemental Content

Loading ...
Support Center